New hepatitis b drug enters first human tests
NCT ID NCT07595159
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This early-stage study tested a new medicine called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see if the drug is safe and how it works against the virus. The main goal was to find any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Argo Investigative Site
Beijing, Beijing Municipality, 100050, China
-
Argo Investigative Site
Chongqing, Chongqing Municipality, 404000, China
-
Argo Investigative Site
Guanzhou, Guangdong, 510700, China
-
Argo Investigative Site
Xuzhou, Jiangsu, 221000, China
Conditions
Explore the condition pages connected to this study.